Selling Superiority at BioStar
BioStar has been able to convince doctor's offices that its diagnostic tests are worth more because of their technological superiority. But an FDA clamp-down and stiff competition are forcing BioStar to look for new opportunities and partners.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.